Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A randomized, controlled, double-blind, multicenter clinical study of Huangqi Guizhi Wuwu Tang granules for the treatment of peripheral neurotoxicity induced by oxaliplatin in colorectal cancer chemotherapy

ABSTRACT: Interventions: Granule group:Subjects were given Huangqi Gui Zhi Wu Wu Wu Tang granules twice a day, once in the morning and once in the evening, one sachet each time, with warm water ;Mimetic group:Subjects were given a simulated dose of 1 sachet twice a day, once in the morning and once in the evening, with warm water. Primary outcome(s): Time to onset, incidence of grade 2 and grade 3 neurotoxicity Study Design: Parallel

DISEASE(S): Peripheral Neurotoxicity Caused By Oxaliplatin For Colorectal Cancer Chemotherapy

PROVIDER: 35304 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Global Mapping at the Core of the Arabidopsis Circadian Clock Defines the Network Structure of the Oscillator

Project description:In many organisms, the circadian clock is composed of functionally coupled morning and evening oscillators that regulate the bouts of dawn and dusk activity. In Arabidopsis, oscillator coupling relies on a core loop in which the evening oscillator component TOC1 was proposed to activate a subset of morning-expressed oscillator genes. Our systems-biological approach overturns the current view of the Arabidopsis circadian clock showing that TOC1 does not function as an activator but as a timely-controlled general repressor of morning and evening oscillator components. Repression occurs through rhythmic binding to the promoters of all oscillator genes, suggesting a previously unexpected direct connection between the morning and evening loops.

2012-03-08 | GSE35952 | GEO

Global Mapping at the Core of the Arabidopsis Circadian Clock Defines the Network Structure of the Oscillator

2012-03-08 | E-GEOD-35952 | biostudies-arrayexpress

Diurnal ChIP-Seq for Petunia hybrida

Project description:To better understand how diurnal transcriptional regulation contributes to day/night cycles of volatile emission from the petunia flower, cross-linked chromatin from corolla in the morning (7AM) and evening (7PM) was immunoprecipitated with antibodies against 4 histone marks associated with trancriptional activity to determine islands enriched for the marks in morning and evening.

2023-11-08 | GSE230857 | GEO

Diurnal RNA-Seq for Petunia hybrida

Project description:To better understand how diurnal transcriptional regulation contributes to day/night cycles of volatile emission from the petunia flower, RNA extracted from corolla in the morning (7AM) and evening (7PM) was sequenced to determine genes differentially expressed at the two time points.

2023-10-24 | GSE230802 | GEO

Impact of circadian rhythm in obtaining reference profiles of exRNAs in healthy individuals (2)

Project description:Blood was collected from healthy individuals in the morning, afternoon and evening, and plasma analyzed by RNA-seq. Plasma from two donors were not included due to excessive hemolysis in samples from two data points. One datapoint -afternoon- from donor 3 was also not included due to excessive hemolysis.

2022-10-12 | GSE214977 | GEO

Bioequivalence study in Metastatic Colorectal Cancer Patients

Project description:Intervention1: 15 mg Trifluridine/6.14 mg Tipiracil and 20 mg Trifluridine/8.19 mg Tipiracil Tablet.: Manufactured by NATCO Pharma Ltd. orally twice daily with approximately 240 mL (8 fluid ounces) of water at ambient temperature after an overnight fast of at least 10 hours Prior to morning dosing and fasting of at least 02 hours prior to evening dosing (except the standard test meal administered 30 minutes prior to dosing) within 30 minutes of completion of morning and evening meals on Cycle 1 (Days 1 through 5) OR Cycle 1 (Day 8 through 12) or Cycle 2 (Days 1 through 5) based on the randomization Schedule. Control Intervention1: LONSURF Tablet; 35 mg/m2 of Trifluridine; Tipiracil Tablet(15 mg Trifluridine/6.14 mg Tipiracil and 20 mg Trifluridine/8.19 mg Tipiracil tablet ): Manufactured by Taiho Pharmaceutical Co., Ltd., Japan. Manufactured for Taiho Oncology, Inc. Princeton, NJ 08540 USA. orally twice daily with approximately 240 mL (8 fluid ounces) of water at ambient temperature after an overnight fast of at least 10 hours Prior to morning dosing and fasting of at least 02 hours prior to evening dosing (except the standard test meal administered 30 minutes prior to dosing) within 30 minutes of completion of morning and evening meals on Cycle 1 (Days 1 through 5) OR Cycle 1 (Day 8 through 12) or Cycle 2 (Days 1 through 5) based on the randomization Schedule Primary outcome(s): To assess relative bioavailability of 15 mg Trifluridine/6.14 mg Tipiracil and 20 mg Trifluridine/8.19 mg Tipiracil Tablet, compared to LONSURF (15 mg Trifluridine/6.14 mg Tipiracil and 20 mg Trifluridine/8.19 mg Tipiracil) Tablet, following multiple dose in Metastatic colorectal cancer patients who have been previously treated with fluoropyrimidine, oxaliplatin, and irinotecan-based chemotherapy, an anti-VEGF therapy, and if KRAS wild type, an anti-EGFR therapy.Timepoint: 33 Days

| 2586699 | ecrin-mdr-crc

Comparison of Moviprep and Prepkit C Bowel preparation in inflammatory bowel disease patients and in the general population

Project description:Interventions: Randomised to two different types of bowel prep: Moviprep or Prep Kit C All patients were provided with the bowel preparation kits and written information explaining appropriate diet changes, instructions on how to prepare and timing of consumption. This information was additionally explained at a face-to-face review in the outpatient clinic up to four weeks before the colonoscopy by either a senior gastroenterologist or a gastroenterology advanced trainee. Arm 1: Moviprep Moviprep comes with two large sachets (sachet A) and two small sachets (sachet B). Each pair of sachets (A and B) is dissolved in one litre of water to make a solution. One litre is taken the evening before the procedure and the other in the early morning on the day of of the colonoscopy. Primary outcome(s): Bowel preparation tolerability as determined by a Tolerability Questionnaire [On day of completion of bowel preparation ] Study Design: Purpose: Diagnosis; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Parallel;Type of endpoint: Safety/efficacy

| 2469860 | ecrin-mdr-crc

Combination Lubiprostone and Split-Dose PEG-ELS Vs Split-Dose PEG-ELS alone for bowel preparation before colonoscopy in constipated patients: A prospective, endoscopist-blinded, randomized controlled trial

Project description:Interventions: split-dose PEG-ELS combination with Lubiprostone 3 times by specifying as follows; 2 days before colonoscopy 1 capsule of Lubiprostone at 6.00 a.m. then took 1 capsule of Lubiprostone at 6 p.m. Day before colonoscopy - 1 capsule of Lubiprostone at 6.00 a.m. The subjects would receive 1 sachet of PEG-ELS mixed with 2 liters of water, which the patients had to take all within 2 hours at 6:00 p.m. Lastly, on the colonoscopy day, the subjects received 1 sachet of PEG-ELS mixed with 2 liters of water and took it all in 2 hours at 4.00 a.m. on the day of the colonoscopy.,split-dose PEG-ELS before colonoscopy day, patients had to take 1 sachet of PEG-ELS with 2 Liter of water at 6 p.m. and 1 sachet of PEG-ELS with 2 Liter of water at 4 a.m. on the day of the colonoscopy.;Active Comparator Drug,Placebo Comparator Drug;split-dose PEG-ELS combination with Lubiprostone 3 times ,split-dose PEG-ELS combination Primary outcome(s): the Ottawa bowel preparation score Colonoscopy day proportion of adequate bowel cleansing Study Design: Randomized

| 56421 | ecrin-mdr-crc

Microglia drive diurnal variation in susceptibility to inflammatory blood-brain barrier breakdown

Project description:The blood brain barrier (BBB) is critical for maintaining brain homeostasis but is susceptible to inflammatory breakdown. Permeability of the BBB to polar molecules shows circadian variation due to rhythmic transporter expression, while basal permeability to polar molecules in non-rhythmic. Whether daily timing influences BBB permeability in response to inflammation is unknown. Here, we induced systemic inflammation through repeated lipopolysaccharide (LPS) injections either in the morning (ZT1) or evening (ZT13) under standard lighting conditions, then examined BBB permeability to a polar molecule. We observed clear diurnal variation in inflammatory BBB permeability, with a striking increase in BBB breakdown specifically following evening LPS injection. Evening LPS led to persisting glia activation and inflammation in the brain that was not observed in the periphery. The exaggerated evening neuroinflammation and BBB disruption were suppressed by microglial depletion, were associated with enhanced expression of the Nos2 gene, and could be prevented in vivo by treatment with an iNOS inhibitor. Our data show that diurnal rhythms in microglial inflammatory responses to LPS drive daily variability in BBB breakdown, and reveals time-of-day as a key regulator of inflammatory BBB disruption.

2024-12-06 | GSE263794 | GEO

To assess the safety and tolerability of a single oral dose of the Capecitabine test and reference formulations

Project description:Intervention1: Capecitabine Tablets 500 mg, manufactured by Hetero labs ltd.: The recommended dose of capacitabine is 1250 mg/m2 administered orally twice daily (morning and evening; equivalent to 2500 mg/m2 total daily dose) for 2 weeks followed by a 1-week rest period given as 3 week cycles Intervention2: Capecitabine Tablets 500 mg,manufactured by Hetero labs ltd.: The recommended dose of capacitabine is 1250 mg/m2 administered orally twice daily (morning and evening; equivalent to 2500 mg/m2 total daily dose) for 2 weeks followed by a 1-week rest period given as 3 week cycles Control Intervention1: XelodaÂ (Capecitabine) Tablets 500 mg (Distributed by Genentech USA, Inc., A Member of the Roche Group, South San Francisco, CA 94080): The recommended dose of XELODAÂ is 1250 mg/m2 administered orally twice daily (morning and evening; equivalent to 2500 mg/m2 total daily dose) for 2 weeks followed by a 1-week rest period given as 3 week cycles Primary outcome(s): Establishing the bioequivalence between test and referenceTimepoint: Day 1 and Day 2

| 2573933 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data